Is Valacyclovir Non-inferior to Valganciclovir as CMV and EBV Prophylaxis in Kidney Transplant Recipients? A Single-Center Prospective Randomized Pilot Study

Abroad (travel likely)Recruiting

Conditions

Kidney Transplantation, Cytomegalovirus Infections · EBV Infection · Antiviral Prophylaxis

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

National Taiwan University Hospital, Taipei, Taiwan
Contact: Study coordinator (Hou-Xuan Huang, MD) · hxhuang@ntuh.gov.tw · 886-2312-3456
Yi-Jen Huang, PharmD (Sub-investigator)
Contact: Principal Investigator (Hou-Xuan Huang, MD)

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Letermovir-based Dual Therapy for Treatment of Cytomegalovirus Infections

Cytomegalovirus Infection

Abroad (travel likely)RecruitingPHASE3

Paris, France · Paris, France

Efficacy and Safety of Leymovir Versus Valganciclovir in Prevention of Cytomegalovirus Infection and Cytomegalovirus Disease in Chinese Kidney Transplant Recipients

Kidney Transplant

Abroad (travel likely)RecruitingPHASE4

Xi'an, China

Letermovir (Prevymis) for CMV in Kidney and Pancreas Transplant Recipients

Cytomegalovirus Infections · Kidney Transplant Infection · Pancreas Transplant

Abroad (travel likely)RecruitingPHASE3

Madison, United States

Strategic Help With Immunoglobulin to Enhance Protect Against Late Disease (CMV)

Cytomegalovirus · Organ Transplant · Kidney Transplant; Complications

Abroad (travel likely)RecruitingPHASE4

Boston, United States · Dallas, United States